Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model

Abstract

It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML). We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl. To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity. Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001. Of interest, mice that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50. We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Arlinghaus RB . 1998 Crit. Rev. Oncogenesis 9: 1–18

  • Braselman S, McCormick F . 1995 EMBO J. 14: 4839–4848

  • Bonnet D, Dick J . 1997 Nat. Med. 3: 730–737

  • Campbell M, Li W, Arlinghaus RB . 1990 Oncogene 5: 773–776

  • Dazzi F, Capelli D, Hasserjian R, Cotter F, Corbo M, Poletti A, Chinswangwatanakul W, Goldman JM, Gordon MY . 1998 Blood 92: 1390–1396

  • Dazzi F, Gordon M, Chinswangwatanakul W, Cotter F, Evans M, Hasserjian R, Grand F, Goldman JM . 1997 Blood 90: Suppl. 1 8

  • Daley GQ, van Etten RA, Baltimore D . 1990 Science 247: 824–830

  • Gross AW, Zhang X, Ren R . 1999 Mol. Cell. Biol. 19: 6918–6928

  • Hawk N, Liu J, Wu Y, Arlinghaus RB . 1997 Blood 90: Suppl. 2 277b

  • Hu A-ZX, Ji W, Zhou Y, Logothetis C, Xu H-J . 1997 Cancer Res. 57: 3339–3343

  • Heisterkamp N, Jenster G, ten Hoeve H, Zovich D, Pattengale PK, Groffen J . 1990 Nature 334: 251–258

  • Huettner D, Zhang P, Van Etten RA, Tenen DG . 2000 Nature Genet. 24: 57–60

  • Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP . 1998 Blood 91: 630–640

  • Li W, Draezen O, Kloetzer WS, Gale RP, Arlinghaus RB . 1989 Oncogene 4: 127–138

  • Lin F, van Rhee F, Goldman JM, Cross NCP . 1996 Blood 87: 4473–4478

  • Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Andersson BS, Arlinghaus RB . 1993 Oncogene 8: 101–109

  • Liu J, Wu Y, Arlinghaus RB . 1996a Cancer Res. 56: 5120–5124

  • Liu J, Wu Y, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB . 1996 Mol. Cell. Biol. 16: 998–1005

  • Lozzio CB, Lozzio BB . 1975 Blood 45: 321–334

  • Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB . 1997 Oncogene 14: 2367–2372

  • Maru ON, Witte ON . 1991 Cell 67: 459–468

  • McWhirter JR, Galasso DL, Wang JYJ . 1993 Mol. Cell. Biol. 13: 7587–7595

  • Muller AJ, Young JC, Pendergast AM, Pondel M, Landau RN, Littman DR, Witte ON . 1991 Mol. Cell. Biol. 11: 1785–1792

  • Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . 1991 Cell 66: 161–171

  • Wu Y, Ma G, Lu D, Lin F, Xu H-J, Liu J, Arlinghaus RB . 1999 Oncogene 18: 4416–4424

  • Wu Y, Liu J, Arlinghaus RB . 1998 Oncogene 16: 141–146

Download references

Acknowledgements

These studies were supported by grant CA16672 and CA49639 from NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, F., Monaco, G., Sun, T. et al. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 20, 1873–1881 (2001). https://doi.org/10.1038/sj.onc.1204409

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204409

Keywords

This article is cited by

Search

Quick links